Randomized trial of cervene, a κ receptor-selective opioid antagonist, in acute ischemic stroke

Journal of Stroke and Cerebrovascular Diseases

Volumn 6, Issue 1, 1996, Pages 35-40

  Clark, W M ^a,c   Coull, B M ^a,c   Karukin, M ^a,c   Hendin, B ^b,c   Kelley, R ^c   Rosing, H ^c   Zachariah, S ^c   Winograd, M ^b,c   Raps, E ^c   Walshe, T ^c   Singer, S ^a,c   Mettinger, K L ^a,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Baker Norton Pharmaceuticals Inc   (United States)

^c NONE

Author keywords

Nalmefene; Opiate antagonist; Stroke; Therapy

Indexed keywords

EID: 0005489840     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-3057(96)80024-3     Document Type: Article

References (28)

1. Rothman S., and Olney J. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 19 (1986) 105-111
2. Olney J.W. Excitotoxins: an overview. In: Fuxe K., Roberts P.J., and Schwarcz R. (Eds). Exitcotoxins (1983), McMillan, London 92-96
3. Faden A.I. Neuropeptides and central nervous system injury. Arch Neurol 43 (1986) 501-504
4. Zivin J.A., and Choi D.W. Stroke therapy. Sci Am 265 (1991) 56-63
5. Grotta J., Clark W., Coull B., et al. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke: results of a phase II a randomized trial. Stroke 26 (1995) 602-605
6. Faden A.I. Role of opiate antagonists in the treatment of stroke. In: Weinstein P.R., and Faden A.I. (Eds). Protection of the brain from ischemia (1990), Williams & Wilkins, Baltimore 265-271
7. Krumins S.A., and Faden A.I. Traumatic injury alters opiate receptor binding in spinal cord. Ann Neurol 19 (1986) 498-501
8. Herman B.H., and Goldstein A. Antinociception and paralysis induced by intrathecal dynorphin. J Pharmacol Exp Ther 232 (1985) 27-32
9. Faden A.I., Molineaux C.J., Rosenberger J.G., Jacobs T.P., and Cox B.M. Increased dynorphin immunoreactivity in spinal cord after traumatic injury. Regul Pept 11 (1985) 35-41
10. Scavini S., Rozza A., Bo P., et al. K-opioid receptor changes and neurophysiological alterations during cerebral ischemia in rabbits. Stroke 21 (1990) 943-947
11. Harini R.J., Supra E.L., Roberts J.P., and Lavyne M.H. Effect of naloxone on cerebral perfusion and cardiac performance during experimental cerebral ischemia. J Neurosurg 64 (1986) 780-786
12. 5)-enkephalinamide, and naloxone on cortical blood flow and cerebral blood volume in experimental brain ischemia in anesthetized cats. J Cereb Blood Flow Metab 6 (1986) 553-558
13. Namba S., Nishigaki S., Fujiwara N., Wani T., Namba Y., and Masaoka T. Opiate-antagonist reversal of neurological deficits: Experimental and clinical studies. Jpn J Psychiatry Neurol 40 (1986) 61-79
14. Fallis R.J., Fisher M., and Lobo R.A. A double blind trial of naloxone in the treatment of acute stroke. Stroke 15 (1984) 627-629
15. Perraro F., Tosocini G., Pertoldi F., et al. Double-blind placebo controlled trial of naloxone on motor deficits in acute cerebrovascular disease. Lancet 1 (1984) 915
16. Hahn E.F., Fishman J., and Heilman R.D. Narcotic antagonists. 4. Carbon-6 deratives of N-substituted noroxymorphones as narcotic antagonists. J Med Chem 18 (1975) 259-262
17. Michel M.E., Bolger G., and Weissman B.A. Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Findings Exp Clin Pharmacol 7 (1985) 175-177
18. Yum S.W., and Faden A.I. Comparison of the neuroprotective effects of the N-methyl-d-aspartate antagonist MK801 and the opiate receptor antagonist nalmefene in experimental spinal cord ischemia. Arch Neurol 47 (1990) 277-281
19. Faden A.I., Shirane R., Chang L.H., James T.L., Lemke M., and Weinstein P.R. Opiate-receptor antagonist improves metabolic recovery and limits neurochemical alterations associated with reperfusion after global brain ischemia in rats. J Pharmacol Exp Ther 255 (1990) 451-460
20. Graham S.H., Shimizu H., Newman A., Weinstein P., and Faden A.I. Opioid receptor antagonist nalmefene stereospecifically inhibits glutamate release during global cerebral ischemia. Brain Res 632 (1993) 346-350
21. Vink S.W., Mcintosh T.K., Rhomhanzi R., and Faden A.I. Opiate antagonist nalmefene improves intracellular free Mg2+, bioenergetic state, and neurologic outcome following traumatic brain injury in rats. J Neurosci 10 (1990) 3524-3530
22. Nalmefene hydrochloride injection for CNS trauma and ischemia. Investigator's Brochure, IVX-B-116 (1995)
23. Lyden P., Brott T., Tilley B., et al. Improved reliability of NIH stroke scale using video training. Stroke 25 (1990) 2220-2226
24. Gillings D., and Koch G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Inform J 25 (1991) 411-424
25. Brott T.G., Haley E.C., Levy D.E., et al. Urgent therapy for stroke: part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 23 (1992) 632-640
26. Haley E.C., Levy D.E., Brott T.G., et al. Urgent therapy for stroke: part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 23 (1992) 641-645
27. Clark W.M., Coull B.M., and for the CGS19755 Study Group. Randomized trial of CGS19755, a glutamate antagonist, in acute ischemic stroke treatment (abstr). Neurology 44 (1994) A270
28. Albers G.W., Atkinson R.P., Kelley R.E., Rosenbaum D.M., and for the Dextrorphan Study Group. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with an acute stroke. Stroke 26 (1995) 254-258